A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally
advanced or metastatic solid tumors. The study is enrolling cohorts of participants with
melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), and
HER2-negative gastric cancerovarian carcinoma, cervical cancer, endometrial cancer, bladder
cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer.